To answer to the global shortage of high-activity Pancrelipase/Pancreatin Enzybel Pharma 2 by Natix, which is a leading European distributor of natural performant bioactives and active pharmaceutical ingredients specializing in ’out-of-nature’ enzymes, is pleased to announce, that it has forged a strategic alliance with Deebio, a prominent Chinese manufacturer of enzymes.
To meet the rigorous standards of transparency, quality, and market commitment required by Enzybel Pharma 2, Deebio is currently building a cutting-edge manufacturing facility dedicated to Pancrelipase – (a highly purified, standardized form of pancreatin) production. This state-of-the-art plant will feature a fully enclosed, highly automated production process that complies with current Good Manufacturing Practices in both the EU and the US, ensuring exceptional quality and regulatory compliance.
Enzybel Pharma 2 has secured exclusive sales rights for Europe and the US markets for the highly important active pharmaceutical ingredient (API) Pancrelipase/Pancreatin with high enzymatic activity. This agreement marks a significant step in our shared mission to provide natural life-saving API´s to patients worldwide.
Pancrelipase/Pancreatin, an essential ingredient for the treatment of pancreatic insufficiency, will play a key role in addressing acute medication shortages in global markets. By securing these exclusive rights, we aim to significantly increase the availability.
The two companies will collaborate closely to optimize the manufacturing and distribution. With a combination of expertise, innovation, and a strong focus on quality, we are confident in our ability to supply this ingredient to the market.
The collaboration between Enzybel Pharma 2 and Deebio will not only boost production but also enhance patient care in multiple countries. We look forward to the positive impact this partnership will have on the health and well-being of patients around the globe.
